Pillar Biosciences to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Randy Pritchard, Pillar Biosciences CEO, highlighted some of the progress the oncology solutions company has made in developing in-vitro diagnostics in response to emailed questions from MedCity News.

NATICK, Mass. – February 10, 2022 – (BUSINESS WIRE) – Pillar Biosciences, an innovative, next-generation sequencing (NGS) solutions, in-vitro diagnostics (IVD) company, today announced that Randy Pritchard, Chief Executive Officer, will present virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 16, 2022, at 12:30pm Eastern Time.

About Pillar Biosciences

Pillar Biosciences is a global oncology solutions company delivering in-vitro diagnostics (IVD) that provide accurate, robust, timely, clinically actionable insights to guide treatment decisions throughout a patient’s continuum of care. We power the oncology ecosystem with our proprietary, automatable, NGS platform agnostic, SLIMamp® and PiVAT® technologies with a simplified workflow to expedite the delivery of robust and dependable clinical test results.

Our mission is to enable access to high quality, affordable, specialty NGS testing, performed by any NGS laboratory as clinical grade tests, closer to home, for all patients. Pillar has operations in Natick, MA and Shanghai, China. For more information, visit www.pillar-biosciences.com.

Investor Contact:
Dawn Schottlandt
Argot Partners
212-600-1902
Pillar@argotpartners.com

Media Contact:
Joshua R. Mansbach
Argot Partners
212-600-1902
Pillar@argotpartners.com

Don’t Stop Here

More To Explore

Pillar Biosciences Presents New Clinical Validation Data Confirming the Accuracy of its oncoReveal™ Dx Lung & Colon Cancer Assay in Detecting Clinically Relevant Variants

– Laboratory and software validation testing determined ability to accurately identify key companion diagnostic targets within KRAS and EGFR genes, and specify associated approved therapy …

Read More →

Pillar Biosciences Expands Leadership Team with Appointment of Daniel Harma as Chief Commercial Officer and Christa Adkins as General Counsel

Randy Pritchard, Pillar Biosciences CEO, highlighted some of the progress the oncology solutions company has made in developing in-vitro diagnostics in response to emailed questions from MedCity News.

Read More →

Pillar Biosciences to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Randy Pritchard, Pillar Biosciences CEO, highlighted some of the progress the oncology solutions company has made in developing in-vitro diagnostics in response to emailed questions from MedCity News.

Read More →

Pillar Biosciences Receives CLIA Certification for its Next-Generation Sequencing Clinical Laboratory

Randy Pritchard, Pillar Biosciences CEO, highlighted some of the progress the oncology solutions company has made in developing in-vitro diagnostics in response to emailed questions from MedCity News.

Read More →

Pillar Biosciences seeks to make precision medicine a first-line therapy for cancer patients

Randy Pritchard, Pillar Biosciences CEO, highlighted some of the progress the oncology solutions company has made in developing in-vitro diagnostics in response to emailed questions from MedCity News.

Read More →

Pillar Biosciences to Collaborate with Labcorp on Precision Genomic Cancer Testing Using Next-Generation Sequencing

NATICK, Mass.–(BUSINESS WIRE)– Pillar Biosciences, an innovative, next-generation sequencing (NGS) solutions, in-vitro diagnostics company, today announced that it has entered into an agreement with Labcorp …

Read More →
WP Feedback

Dive straight into the feedback!
Login below and you can start commenting using your own user instantly

Scroll to Top